$-0.69 EPS Expected for Zealand Pharma A/S (ZEAL); Fabrinet Ordinary Shares (FN) Shorts Lowered By 38.55%

Analysts expect Zealand Pharma A/S (NASDAQ:ZEAL) to report $-0.69 EPS on March, 6.They anticipate $0.11 EPS change or 18.97% from last quarter’s $-0.58 EPS. After having $4.69 EPS previously, Zealand Pharma A/S’s analysts see -114.71% EPS growth. The stock increased 2.85% or $0.4 during the last trading session, reaching $14.42. About 1,542 shares traded. Zealand Pharma A/S (NASDAQ:ZEAL) has declined 1.71% since February 11, 2018 and is downtrending. It has underperformed by 1.71% the S&P500. Some Historical ZEAL News: 20/03/2018 – REG-Zealand Pharma’s first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective; 20/03/2018 – Zealand Pharma’s first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective; 22/03/2018 – REG-Zealand Pharma convenes its Annual General Meeting 2018; 16/05/2018 – ZEALAND PHARMA A/S ZELA.CO – MAINTAINS ITS FINANCIAL GUIDANCE FOR FULL-YEAR 2018; 31/05/2018 – ZEALAND PHARMA ON TRACK TO INITIATE GLEPAGLUTIDE PHASE 3 IN 2H; 02/05/2018 – Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018; 11/04/2018 – ZEALAND PHARMA A/S ZELA.CO – HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE; 07/03/2018 – Zealand Pharma 2017 full-year results in line with guidance – considerable progress in the clinical portfolio; 16/05/2018 – Zealand Pharma – Interim report for the first quarter of 2018; 11/04/2018 – Zealand and Roche Diabetes Care Enter Phase 3 Study Collaboration for Treatment of Congenital Hyperinsulinism With Dasiglucagon

Fabrinet Ordinary Shares (NYSE:FN) had a decrease of 38.55% in short interest. FN’s SI was 542,700 shares in February as released by FINRA. Its down 38.55% from 883,100 shares previously. With 591,400 avg volume, 1 days are for Fabrinet Ordinary Shares (NYSE:FN)’s short sellers to cover FN’s short positions. The SI to Fabrinet Ordinary Shares’s float is 1.52%. The stock increased 1.97% or $1.01 during the last trading session, reaching $52.36. About 239,991 shares traded. Fabrinet (NYSE:FN) has risen 53.29% since February 11, 2018 and is uptrending. It has outperformed by 53.29% the S&P500. Some Historical FN News: 15/05/2018 – Alyeska Investment Group Buys New 1.3% Position in Fabrinet; 22/05/2018 – Fabrinet Presenting at Conference Tomorrow; 01/05/2018 – Pekin Singer Strauss Asset Mgmt Buys 1.3% Position in Fabrinet; 16/04/2018 – FABRINET SAYS “ZTE IS NOT A DIRECT FABRINET CUSTOMER”; 07/05/2018 – Fabrinet Sees 4Q Adj EPS 73c-Adj EPS 77c; 07/05/2018 – Fabrinet 3Q EPS 55c; 02/04/2018 Fidelity Select Telecommunications Adds Fabrinet; 07/05/2018 – FABRINET 3Q ADJ EPS 71C, EST. 71C; 07/05/2018 – Fabrinet 3Q Rev $332.2M; 11/05/2018 – Fabrinet Presenting at Conference May 23

Investors sentiment increased to 1.33 in 2018 Q3. Its up 0.26, from 1.07 in 2018Q2. It improved, as 13 investors sold Fabrinet shares while 56 reduced holdings. 45 funds opened positions while 47 raised stakes. 33.32 million shares or 7.30% less from 35.95 million shares in 2018Q2 were reported. Renaissance Technologies Lc holds 0% or 34,500 shares. 9,969 are owned by Hbk Invs L P. Prudential Fincl holds 0% of its portfolio in Fabrinet (NYSE:FN) for 59,679 shares. Invesco Limited reported 210,510 shares. Riverhead Capital Ltd Liability Co has invested 0.01% in Fabrinet (NYSE:FN). Vaughan Nelson Inv Management Ltd Partnership holds 0.58% in Fabrinet (NYSE:FN) or 1.08M shares. Credit Suisse Ag owns 30,158 shares for 0% of their portfolio. Scout Invests accumulated 0.08% or 82,007 shares. Parkside Bancorporation Trust reported 30 shares. Miles holds 0.17% in Fabrinet (NYSE:FN) or 4,494 shares. Bluemountain Capital Mgmt Lc reported 2,389 shares. Meeder Asset Management Incorporated, Ohio-based fund reported 5,612 shares. Ameritas Prns has 0.01% invested in Fabrinet (NYSE:FN) for 3,011 shares. Moreover, Stratos Wealth Prns Limited has 0% invested in Fabrinet (NYSE:FN) for 100 shares. Wasatch Advsr reported 672,486 shares.

Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of optical communication components, modules and sub-systems, industrial lasers, medical devices, and sensors. The company has market cap of $1.93 billion. It offers a range of optical and electro-mechanical capabilities across the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, packaging, integration, final assembly, and test. It has a 19.13 P/E ratio. The companyÂ’s products comprise switching products, such as reconfigurable optical add-drop multiplexers, optical amplifiers, modulators, and other optical components and modules that enable network managers to route voice, video, and data communications traffic through fiber optic cables at various wavelengths and speeds, and over various distances; tunable lasers, transceivers, and transponders; and active optical cables, which provide high-speed interconnect capabilities for data centers and computing clusters, as well as for Infiniband, Ethernet, fiber channel, and optical backplane connectivity.

Among 4 analysts covering Fabrinet (NYSE:FN), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Fabrinet had 6 analyst reports since August 16, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, October 23. The company was downgraded on Tuesday, August 21 by Needham. The firm has “Buy” rating by Needham given on Wednesday, September 5. The stock of Fabrinet (NYSE:FN) earned “Buy” rating by FBR Capital on Thursday, August 16. As per Tuesday, September 4, the company rating was downgraded by FBR Capital.

More notable recent Fabrinet (NYSE:FN) news were published by: Benzinga.com which released: “Fabrinet (NYSE:FN) – Q2 Earnings Preview For Fabrinet – Benzinga” on February 04, 2019, also Benzinga.com with their article: “Earnings Scheduled For February 4, 2019 – Benzinga” published on February 04, 2019, Seekingalpha.com published: “Fabrinet Has A Very Solid Quarter – Seeking Alpha” on August 23, 2018. More interesting news about Fabrinet (NYSE:FN) were released by: Seekingalpha.com and their article: “Fabrinet: Gearing Up For A Rebound? – Seeking Alpha” published on May 09, 2018 as well as Benzinga.com‘s news article titled: “B. Riley Downgrades Fabrinet (NYSE:FN), II-VI (NASDAQ:IIVI), Says Optical Companies ‘Will Suffer The Consequences’ Of Tariffs – Benzinga” with publication date: September 04, 2018.

Since August 23, 2018, it had 0 insider purchases, and 8 insider sales for $10.40 million activity. $1.91M worth of Fabrinet (NYSE:FN) was sold by Ng Toh-Seng. Shares for $240,130 were sold by Olson Rollance E.. Shares for $1.82 million were sold by Mitchell David T.. $313,396 worth of stock was sold by Grady Seamus on Thursday, November 15. The insider Gill Harpal sold $1.74 million.

More notable recent Zealand Pharma A/S (NASDAQ:ZEAL) news were published by: Nasdaq.com which released: “European ADRs Move Lower in Monday Trading – Nasdaq” on February 11, 2019, also Nasdaq.com with their article: “European ADRs Move Lower in Friday Trading – Nasdaq” published on February 08, 2019, Nasdaq.com published: “The Stock Symbol All Weed Companies Want – Nasdaq” on February 01, 2019. More interesting news about Zealand Pharma A/S (NASDAQ:ZEAL) were released by: Globenewswire.com and their article: “Changes to Zealand Pharma’s Executive Management Copenhagen Stock Exchange:ZEAL – GlobeNewswire” published on January 23, 2019 as well as Nasdaq.com‘s news article titled: “European ADRs Move Higher in Tuesday Trading – Nasdaq” with publication date: January 15, 2019.

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide medicines in Denmark. The company has market cap of $448.92 million. The firm markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. It has a 4.8 P/E ratio. The Company’s products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes.

Fabrinet (NYSE:FN) Ratings Chart